Want to start a career in AI? Explore the top AI jobs in India for 2026, including ML Engineer salaries, required skills like ...

Amazon One Medical launched a GLP-1 program integrating obesity care with Amazon Pharmacy. Pricing for the popular weight loss drugs will begin at as low as $25 per month with insurance. Shares of ...

The 2026 UFL season opened Friday with new teams, new coaches, new players, new uniforms and new rules. [2026 UFL: Everything To Know About the 2026 UFL Season] Kicking things off on FOX UFL Friday, ...

U.S. jobs data and eurozone provisional inflation figures for March will attract attention in the coming week as data begins to give a picture of how the war in the Middle East, and particularly the ...

Editor's note: This is the first of three feature articles Ars is publishing to explore the financial, technical, and competitive dimensions of orbital data centers. Although the idea of putting data ...

Provisional purchasing managers’ surveys for March in the U.S. and Europe in the week will provide a key gauge of how the ongoing war in the Middle East has impacted sentiment and business activity.

Structure Therapeutics reported highly positive Phase 2 ACCESS II data for aleniglipron, achieving ~16% placebo-adjusted weight loss with strong statistical significance and no plateau. Aleniglipron’s ...

In an exclusive interview, Google’s new AI infrastructure chief says the tech giant has a “significant investment” planned. At current levels, Forbes projects it could be a very big number indeed.

If you've been eyeing a Hyrox race, but weren't sure how to train for one, Peloton may have just solved your problem. The fitness platform announced today the launch of a 12-week Hyrox training ...

The Dow hit record highs at the start of the week but stumbled into the weekend For years, this rule kept most traders on the sidelines. Now, the door is opening to a whole new wave of active traders.

This year could be a key one for Structure, as the company's GLP-1 weight loss pill, aleniglipron, enters phase 3 trials. If the results prove to be strong, then it may only be a matter of time before ...